Literature DB >> 6437671

Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.

S R Keyes, P M Fracasso, D C Heimbrook, S Rockwell, S G Sligar, A C Sartorelli.   

Abstract

Hypoxic cells of solid tumors are difficult to eradicate by X-irradiation or chemotherapy; as an approach to this problem, our laboratories are investigating the effects of the bioreductive alkylating agent mitomycin C (MC) on hypoxic cells. This antibiotic was preferentially toxic to EMT6 mouse mammary tumor cells and V79 Chinese hamster lung fibroblasts under hypoxic conditions, but it was equitoxic to Chinese hamster ovary cells in the presence and absence of oxygen. All cell lines catalyzed the formation of reactive metabolites under hypoxic conditions and contained NADPH:cytochrome c reductase and DT-diaphorase, two enzymes which may be responsible for the cellular activation of MC. Although a correlation existed between enzymatic activities and the formation of reactive metabolites from MC, there was no correspondence between these parameters and the degree of cytotoxicity expressed by MC under hypoxic conditions. Purified NADPH:cytochrome c reductase reduced MC in the absence of oxygen, with addition of cytochrome P-450 enhancing, but not participating directly in, the reduction reaction. Addition of NADP+ to cell sonicates substantially reduced NADPH:cytochrome c reductase activity, while the formation of reactive metabolites was affected only slightly; converse results were observed using mersalyl. Exposure of cell sonicates to dicumarol inhibited DT-diaphorase activity, while the rate of formation of reactive metabolites of MC was enhanced. The findings suggest that NADPH:cytochrome c reductase and some as yet to be identified enzyme(s) are important for the reductive activation of MC. DT-diaphorase and cytochrome P-450 are not directly involved in the activation of MC, but they appear to modulate the degree of activation to reactive species, which are presumably responsible for the observed cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437671

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Distinct roles of cytochrome P450 reductase in mitomycin C redox cycling and cytotoxicity.

Authors:  Yun Wang; Joshua P Gray; Vladimir Mishin; Diane E Heck; Debra L Laskin; Jeffrey D Laskin
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

2.  A quantitative histochemical study of NADPH-ferrihemoprotein reductase activity.

Authors:  C J Van Noorden; R G Butcher
Journal:  Histochem J       Date:  1986-07

Review 3.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 4.  When you're strange: Unusual features of the MUTYH glycosylase and implications in cancer.

Authors:  Alan G Raetz; Sheila S David
Journal:  DNA Repair (Amst)       Date:  2019-06-08

Review 5.  Cellular pharmacology of quinone bioreductive alkylating agents.

Authors:  S Rockwell; A C Sartorelli; M Tomasz; K A Kennedy
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 6.  Tumor hypoxia: its impact on cancer therapy.

Authors:  J E Moulder; S Rockwell
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism.

Authors:  S Kerpel-Fronius; J Verwey; M Stuurman; B Kanyár; P Lelieveld; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase.

Authors:  J J Schlager; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Isolation and characterization of a mitomycin C-resistant variant of human colon carcinoma HT-29 cells.

Authors:  J H Lee; M Naito; M Nakajima; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Mitomycins syntheses: a recent update.

Authors:  Jean-Christophe Andrez
Journal:  Beilstein J Org Chem       Date:  2009-07-08       Impact factor: 2.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.